Scholarlink

Background <p>Lichen planus (LP) is a group of chronic inflammatory disorders of the skin, mucous membranes, scalp, and nails that mainly affect the middle-aged population. Inflammatory modifiers, including interferon-α (IFN-α), IFN-γ, tumor necrosis factor-alpha (TNF-α), as well as various interleukins (ILs), such as IL-4, IL-5, IL-6, IL-8, IL-9, IL-10, IL-12, IL-17, IL-18, IL-21, IL-22, and IL-23 has also been suggested to contribute in the LP pathogenesis. We aim to systematically evaluate the effect of IL inhibitors on treating and triggering LP disease.</p> Methods <p>A systematic search was conducted up to January 30th, 2025, in PubMed/Medline, Web of Science, and Ovid-Embase, and clinical studies with available English full-text were included.</p> Results <p>The search recorded 196 relevant studies, with 42 articles eligible for this study. IL-inhibitors, including dupilumab, secukinumab, anakinra, tildrakizumab, guselkumab, ustekinumab, ixekizumab, risankizumab, and brodalumab were associated with clinical improvement in various types of LP. In contrast, in some cases with a coexistent autoimmune disease, such as psoriasis and atopic dermatitis, secukinumab, dupilumab, risankizumab, ustekinumab, and ixekizumab administration resulted in LP development.</p> Conclusion <p>IL inhibitors demonstrate both treatment and paradoxical effects on LP. Further research is needed to elucidate the impact of these agents on the pathophysiology of LP.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A systematic review of the role of interleukin inhibitors in lichen planus: therapeutic and paradoxical effects

  • 期刊论文

  • 发表日期：

    2025年8月12日

查看全文
  • Amirhossein Heidari,
  • Fatemeh Fathabadi,
  • Kimia Ghanavati,
  • Asma Rasouli,
  • Sanaz Soleimani,
  • Nazila Heidari

摘要

Background

Lichen planus (LP) is a group of chronic inflammatory disorders of the skin, mucous membranes, scalp, and nails that mainly affect the middle-aged population. Inflammatory modifiers, including interferon-α (IFN-α), IFN-γ, tumor necrosis factor-alpha (TNF-α), as well as various interleukins (ILs), such as IL-4, IL-5, IL-6, IL-8, IL-9, IL-10, IL-12, IL-17, IL-18, IL-21, IL-22, and IL-23 has also been suggested to contribute in the LP pathogenesis. We aim to systematically evaluate the effect of IL inhibitors on treating and triggering LP disease.

Methods

A systematic search was conducted up to January 30th, 2025, in PubMed/Medline, Web of Science, and Ovid-Embase, and clinical studies with available English full-text were included.

Results

The search recorded 196 relevant studies, with 42 articles eligible for this study. IL-inhibitors, including dupilumab, secukinumab, anakinra, tildrakizumab, guselkumab, ustekinumab, ixekizumab, risankizumab, and brodalumab were associated with clinical improvement in various types of LP. In contrast, in some cases with a coexistent autoimmune disease, such as psoriasis and atopic dermatitis, secukinumab, dupilumab, risankizumab, ustekinumab, and ixekizumab administration resulted in LP development.

Conclusion

IL inhibitors demonstrate both treatment and paradoxical effects on LP. Further research is needed to elucidate the impact of these agents on the pathophysiology of LP.